Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,663 | -16,603 | -6,169 | -12,148 | -17,651 |
| Depreciation Amortization | 7,749 | 4,940 | 2,460 | 9,230 | 6,805 |
| Accounts receivable | 3,901 | 10,153 | 4,235 | -7,332 | -7,595 |
| Accounts payable and accrued liabilities | 2,324 | 96 | 615 | -1,784 | 10 |
| Other Working Capital | 13,213 | 9,954 | 1,847 | -10,509 | -6,670 |
| Other Operating Activity | 11,858 | 1,621 | 969 | 27,824 | 20,870 |
| Operating Cash Flow | $23,382 | $10,161 | $3,957 | $5,281 | $-4,231 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -16,812 | -1,985 | -5,132 | -43,935 | -74,563 |
| PPE Investments | -2,534 | -1,544 | -567 | -4,648 | -3,148 |
| Net Acquisitions | N/A | N/A | N/A | -44,896 | -44,896 |
| Purchase Of Investment | N/A | N/A | N/A | -236 | -235 |
| Purchase Sale Intangibles | -195 | -203 | -55 | -179 | -118 |
| Other Investing Activity | -195 | -203 | -55 | -179 | -118 |
| Investing Cash Flow | $-19,541 | $-3,732 | $-5,754 | $-93,894 | $-122,960 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,396 | 1,391 | 1,394 | N/A | 0 |
| Debt Repayment | -418 | -278 | -139 | -565 | -425 |
| Common Stock Issued | 877 | 730 | 506 | 1,468 | 1,127 |
| Common Stock Repurchased | -13,613 | -1,663 | 0 | -42,296 | -8,443 |
| Other Financing Activity | -424 | -278 | -148 | -419 | -317 |
| Financing Cash Flow | $-12,182 | $-98 | $1,613 | $-41,812 | $-8,058 |
| Exchange Rate Effect | 3,014 | 3,957 | 1,695 | -1,445 | -622 |
| Beginning Cash Position | 167,630 | 167,630 | 167,630 | 299,500 | 299,500 |
| End Cash Position | 162,303 | 177,918 | 169,141 | 167,630 | 163,629 |
| Net Cash Flow | $-5,327 | $10,288 | $1,511 | $-131,870 | $-135,871 |
| Free Cash Flow | |||||
| Operating Cash Flow | 23,382 | 10,161 | 3,957 | 5,281 | -4,231 |
| Capital Expenditure | -2,631 | -1,620 | -567 | -4,648 | -3,148 |
| Free Cash Flow | 20,751 | 8,541 | 3,390 | 633 | -7,379 |